What Are Mesenchymal Stem Cells?

First identified in bone marrow stroma in the 1960s, these multipotent cells self-renew and differentiate into bone, cartilage, and fat lineages. First described in bone marrow by Alexander Friedenstein and colleagues in the 1960s, they sit between embryonic stem cells (which form every tissue) and mature adult cells (which have a fixed fate). You can isolate them from bone marrow, fat, umbilical cord, and several other tissues, then expand them in culture while preserving their defining surface markers.

If you’re curious about the science behind one of regenerative medicine’s most talked-about cell types, this walkthrough explores what mesenchymal stem cells are, how researchers isolate and characterize them, and where current clinical applications stand.

The Basic Biology Behind Mesenchymal Stem Cells

Friedenstein’s original work showed that a small fraction of bone marrow cells stuck to plastic culture dishes and grew into fibroblast-like colonies. Those colonies rebuilt a hematopoietic microenvironment when transplanted under a mouse kidney capsule, hinting at a supportive stromal role. Arnold Caplan later popularized the term “mesenchymal stem cell” for cells capable of forming mesoderm-derived tissues, a definition the field still builds on.

On the potency spectrum, MSCs occupy the middle ground. Embryonic stem cells and induced pluripotent stem cells can generate every cell type in the body. Hematopoietic stem cells stay restricted to blood lineages. MSCs reliably produce bone, cartilage, and fat under controlled conditions but do not normally form ectoderm or endoderm tissues in vivo. That mid-range potency, paired with relatively easy expansion, is what makes them so widely studied.

How MSCs Differ From Their Hematopoietic Neighbors

Bone marrow houses at least two distinct stem populations. Hematopoietic stem cells rebuild the blood and immune system. MSCs generate structural connective tissues and provide trophic support to the surrounding niche. The two share an anatomical neighborhood but carry different surface markers, fulfill different roles, and respond to different growth cues. Recognizing this separation matters, because many commercial “stem cell” claims blur the two populations together.

This ambiguity in the literature is exactly why rigorous identification standards were developed.

How Scientists Identify and Characterize MSCs in the Lab

Before any cell product earns the MSC label, it must satisfy criteria the International Society for Cell & Gene Therapy (ISCT) established in 2006. Those standards are now the practical definition across academic labs and registered trials on ClinicalTrials.gov.

The ISCT 2006 Minimum Criteria

Three benchmarks must all hold for a population to be called mesenchymal stem cells in the formal sense:

• ▸Plastic adherence: Cells must attach to standard culture plastic within 24 to 48 hours under standard conditions.
• ▸Positive surface markers: At least 95% of the population must express CD73, CD90, and CD105 when analyzed by flow cytometry.
• ▸Negative surface markers: The same population must show no more than 2% expression of CD34, CD45, CD11b, CD19, or HLA-DR, which mark hematopoietic and endothelial lineages.

Trilineage Differentiation as Functional Proof

Beyond surface markers, the cells must demonstrate differentiation into three lineages when placed in the right induction media. Osteogenic differentiation produces mineralized bone nodules stained by Alizarin Red. Chondrogenic differentiation generates cartilage pellets rich in type II collagen and proteoglycans. Adipogenic differentiation yields lipid-filled vacuoles detectable with Oil Red O. Functional assays remain the gold standard, because no single marker uniquely identifies MSCs.

“Tip: When evaluating any stem cell clinic, ask whether the product has been tested for CD73, CD90, CD105, and the absence of CD34 and CD45, and whether trilineage differentiation has been documented.

Where MSCs Are Found and How They Are Harvested

Bone marrow remains the classical source, but it is no longer the only one. Researchers have isolated MSCs from adipose tissue, umbilical cord Wharton’s jelly, dental pulp, placenta, amniotic fluid, and even peripheral blood under specific mobilization protocols. Each tissue offers a different balance of yield, invasiveness, and donor characteristics.

Comparing Common Tissue Sources

Trade-Offs Between Accessibility and Cell Quality

Adipose-derived MSCs are abundant, but donor age and metabolic status can shift their secretory profile. Bone marrow MSCs are well characterized, yet yields drop sharply with donor age. Umbilical cord MSCs are young and proliferative, but require coordination with birth and carry their own logistical hurdles. Choosing a source always means weighing donor invasiveness, expansion capacity, and the regulatory pathway attached to that specific tissue.

Where the cells come from directly shapes which of these mechanisms a clinician can realistically deploy.

The Mechanisms That Give MSCs Their Therapeutic Potential

Early MSC research framed these cells as miniature building blocks that could replace damaged tissue. The picture has grown more complex. While trilineage differentiation is real, most of the therapeutic signal in current studies appears to come from what MSCs secrete rather than what they directly become.

Differentiation, the Original Model

Under the right signals, MSCs can become osteoblasts that deposit mineralized matrix, chondrocytes that maintain cartilage, and adipocytes that store lipid. Preclinical bone-defect and cartilage-injury models have shown engraftment and matrix deposition, though engraftment rates in human trials remain modest. Differentiation still matters for orthopedic and dental applications where structural repair is the goal.

Paracrine Signaling and Extracellular Vesicles

MSCs release cytokines, growth factors, and extracellular vesicles that modulate inflammation, support angiogenesis, and reduce fibrosis. Vesicles carrying microRNAs and proteins can influence neighboring cells without requiring direct MSC engraftment. This paracrine activity helps explain why low-dose MSC infusions sometimes produce measurable effects in animal models of lung injury, sepsis, or stroke.

Immunomodulation and Low MHC Class II Expression

MSCs suppress T-cell proliferation, dampen B-cell activation, and inhibit NK-cell cytotoxicity through both cell-contact signals and soluble mediators such as indoleamine 2,3-dioxygenase. They express low levels of major histocompatibility complex class II (MHC-II), which reduces their visibility to alloreactive immune cells. That profile, often called hypoimmunogenic, is what allows MSC products from unrelated donors to be tested in allogeneic settings. Even so, immunogenicity is not zero, and immune memory responses have appeared in some repeat-dose studies.

Clinical Applications and Approved MSC-Based Therapies

Clinical interest in MSCs spans orthopedics, autoimmune disease, and transplant complications. Trial registries list hundreds of active studies, though most remain early phase and many are small.

Major Indications Under Investigation

Osteoarthritis trials test intra-articular MSC injections for pain relief and cartilage preservation. Graft-versus-host disease (GvHD) studies focus on systemic infusions for steroid-refractory cases, building on early pediatric work that suggested benefit. Autoimmune conditions such as Crohn’s disease, systemic lupus erythematosus, and multiple sclerosis are being explored because of the immunomodulatory properties described above. Smaller studies have looked at acute respiratory distress syndrome, liver cirrhosis, and diabetic foot ulcers.

Regional Approval Landscape

Several MSC-based products have received conditional or full approval outside the United States. Japan’s conditional approval pathway has authorized products for GvHD and certain cartilage defects. South Korea has approved a cord-blood-derived MSC therapy for GvHD, and European regulators have greenlit a small number of tissue-engineered products containing MSCs. In the United States, the U.S. Food and Drug Administration (FDA) has not broadly approved MSC therapies. Hematopoietic progenitor cell products from cord blood remain the principal FDA-cleared cellular therapy related to the broader stem cell field, and they are not MSC products.

“Warning: Any clinic in the U.S. offering “stem cell” injections for orthopedic, neurological, or anti-aging purposes should be approached with caution. Unproven offerings have triggered FDA enforcement actions and patient harm reports.

How to Tell Research From Marketing

Legitimate MSC research is registered, peer-reviewed, and conducted under an Investigational New Drug (IND) framework when needed. Marketing clinics often skip all three. Ask whether the procedure is part of a registered clinical trial, whether the cells have been characterized to ISCT standards, and whether the clinic provides the actual source, dose rationale, and outcome data in writing.

The Limits, Controversies, and Open Questions in MSC Research

Decades of work have clarified what MSCs are, but the field is still working through what they are not. Honest discussion of those limits is part of understanding the science.

The Mesenchymal Stem Cell vs Mesenchymal Stromal Cell Distinction

Several researchers, including Caplan himself in later years, have argued that many cells labeled “mesenchymal stem cells” are better described as “mesenchymal stromal cells.” The shorthand “MSC” covers both. The distinction matters because true self-renewing stem cell behavior is harder to demonstrate than broad mesenchymal differentiation. The ISCT position paper supports keeping the broader “stromal” framing for most cultured populations.

Reproducibility and Manufacturing Variability

Donor age, tissue source, isolation method, expansion medium, passage number, and cryopreservation protocol all influence MSC behavior. Two products labeled “MSCs” can behave differently in the same assay. Standardizing manufacturing under good manufacturing practice (GMP) conditions helps, but full harmonization across labs remains a work in progress.

Preclinical Promise vs Confirmed Clinical Efficacy

Animal studies consistently show benefit across inflammatory, fibrotic, and degenerative models. Human randomized trials have produced mixed results, with some osteoarthritis and GvHD studies showing modest improvements and others failing to meet primary endpoints. Mesoblast and other companies have reported Phase 3 outcomes in indications like chronic heart failure and GvHD, with regulators scrutinizing efficacy claims. Watch the next wave of large, well-controlled trials, especially those with prespecified endpoints and long-term follow-up, because that is where the field will either consolidate its claims or reset expectations.

Until those trials report, a clear-eyed summary of what is and isn’t settled is worth keeping close.

Final Thoughts

Few cell populations spark as much biological fascination and clinical controversy across modern medicine as this one. Their defining features (plastic adherence, specific surface markers, trilineage differentiation) give researchers a clear handle on identity, while their paracrine and immunomodulatory behavior drives most of the current therapeutic interest. Treat marketing claims with the same skepticism you would apply to any unproven intervention, and follow the registered trial literature as the most reliable source of progress.

FAQ